OBJECTIVE: To describe the application of pharmaceutical care practices in the administration of new therapeutic radiopharmaceuticals used in the treatment of @entity1893 ( @entity1893 ). PRACTICE DESCRIPTION: At the Antibody Labeling Facility at the University of Nebraska Medical Center, the nuclear pharmacist provides support in the formulation, preparation, and quality testing of radiopharmaceuticals. The nuclear pharmacist also provides direct @entity1 care by assisting in the administration of radiopharmaceuticals, monitoring @entity1 during their infusions, and counseling @entity1 on radioimmunotherapy and radiation safety. PRACTICE INNOVATION: Expanding the role of the nuclear pharmacist in treating @entity1 with @entity1893 using radiolabeled monoclonal antibodies (MABs). INTERVENTIONS: The nuclear pharmacist provides specialized pharmaceutical care by being involved in planning @entity1 care, administering diagnostic and therapeutic radiopharmaceuticals, performing individualized @entity1 dose calculations, monitoring @entity1 , and counseling @entity1 . MAIN OUTCOME MEASURES: Number of @entity1 treated with radiolabeled MABs. RESULTS: Since January 1996, 85 @entity1 with @entity1893 have been treated using 131I-tositumomab (Corixa, GlaxoSmithKline), an anti-B1 MAB, under various clinical research protocols requiring specialized pharmaceutical care. The nuclear pharmacist on the team provided direct @entity1 care, assisting with the administration of diagnostic and therapeutic radiopharmaceuticals under a collaborative agreement with a nuclear medicine physician or a radiation oncologist. Other pharmaceutical care activities performed include calculating individual @entity1 doses, obtaining medication histories, counseling @entity1 on their therapy and on radiation safety after early release, and monitoring @entity1 for adverse effects during medication infusion. @entity1 have responded favorably to nontraditional nuclear pharmacy activities. CONCLUSION: The nuclear pharmacist has become an important member of the health care team that provides a new and unique therapy for @entity1 with @entity1893 . To date, the nuclear pharmacist, in collaboration with the nuclear medicine physician or the radiation oncologist, has successfully administered the tositumomab and 131I-tositumomab combination therapy without significant incident.

Combination therapy for XXXX : an opportunity for pharmaceutical care in a specialty practice.

@entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']
@entity1893 :: (MESH:D008228,Disease) :: ['non-Hodgkin's lymphoma']
